Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 145 to 150 of 150 entries
Sorted by: Best Match Show Resources per page
Peanut Can Be Used as a Reference Allergen for Hazard Characterization in Food Allergen Risk Management: A Rapid Evidence Assessment and Meta-Analysis.

The journal of allergy and clinical immunology. In practice

Turner PJ, Patel N, Ballmer-Weber BK, Baumert JL, Blom WM, Brooke-Taylor S, Brough H, Campbell DE, Chen H, Chinthrajah RS, Crevel RWR, Dubois AEJ, Ebisawa M, Elizur A, Gerdts JD, Gowland MH, Houben GF, Hourihane JOB, Knulst AC, La Vieille S, López MC, Mills ENC, Polenta GA, Purington N, Said M, Sampson HA, Schnadt S, Södergren E, Taylor SL, Remington BC.
PMID: 34438104
J Allergy Clin Immunol Pract. 2022 Jan;10(1):59-70. doi: 10.1016/j.jaip.2021.08.008. Epub 2021 Aug 23.

Regional and national legislation mandates the disclosure of "priority" allergens when present as an ingredient in foods, but this does not extend to the unintended presence of allergens due to shared production facilities. This has resulted in a proliferation...

Cite
Turner PJ, Patel N, Ballmer-Weber BK, et al. Peanut Can Be Used as a Reference Allergen for Hazard Characterization in Food Allergen Risk Management: A Rapid Evidence Assessment and Meta-Analysis. J Allergy Clin Immunol Pract. 2021;10(1):59-70doi: 10.1016/j.jaip.2021.08.008.
Turner, P. J., Patel, N., Ballmer-Weber, B. K., Baumert, J. L., Blom, W. M., Brooke-Taylor, S., Brough, H., Campbell, D. E., Chen, H., Chinthrajah, R. S., Crevel, R. W. R., Dubois, A. E. J., Ebisawa, M., Elizur, A., Gerdts, J. D., Gowland, M. H., Houben, G. F., Hourihane, J. O. B., Knulst, A. C., La Vieille, S., López, M. C., Mills, E. N. C., Polenta, G. A., Purington, N., Said, M., Sampson, H. A., Schnadt, S., Södergren, E., Taylor, S. L., & Remington, B. C. (2022). Peanut Can Be Used as a Reference Allergen for Hazard Characterization in Food Allergen Risk Management: A Rapid Evidence Assessment and Meta-Analysis. The journal of allergy and clinical immunology. In practice, 10(1), 59-70. https://doi.org/10.1016/j.jaip.2021.08.008
Turner, Paul J, et al. "Peanut Can Be Used as a Reference Allergen for Hazard Characterization in Food Allergen Risk Management: A Rapid Evidence Assessment and Meta-Analysis." The journal of allergy and clinical immunology. In practice vol. 10,1 (2022): 59-70. doi: https://doi.org/10.1016/j.jaip.2021.08.008
Turner PJ, Patel N, Ballmer-Weber BK, Baumert JL, Blom WM, Brooke-Taylor S, Brough H, Campbell DE, Chen H, Chinthrajah RS, Crevel RWR, Dubois AEJ, Ebisawa M, Elizur A, Gerdts JD, Gowland MH, Houben GF, Hourihane JOB, Knulst AC, La Vieille S, López MC, Mills ENC, Polenta GA, Purington N, Said M, Sampson HA, Schnadt S, Södergren E, Taylor SL, Remington BC. Peanut Can Be Used as a Reference Allergen for Hazard Characterization in Food Allergen Risk Management: A Rapid Evidence Assessment and Meta-Analysis. J Allergy Clin Immunol Pract. 2022 Jan;10(1):59-70. doi: 10.1016/j.jaip.2021.08.008. Epub 2021 Aug 23. PMID: 34438104.
Copy Download .nbib Format: NLM
Renal hemofiltration prevents metabolic acidosis and reduces inflammation during normothermic machine perfusion of the vascularized composite allograft: A preclinical study.

Artificial organs

Stone JP, Amin KR, Geraghty A, Kerr J, Shaw M, Dabare D, Wong JK, Brough D, Entwistle TR, Montero-Fernandez A, Fildes JE.
PMID: 34662442
Artif Organs. 2022 Feb;46(2):259-272. doi: 10.1111/aor.14089. Epub 2021 Nov 26.

INTRODUCTION: Recent experimental evidence suggests normothermic machine perfusion of the vascularized composite allograft results in improved preservation compared to static cold storage, with less reperfusion injury in the immediate post-operative period. However, metabolic acidosis is a common feature of...

Cite
Stone JP, Amin KR, Geraghty A, et al. Renal hemofiltration prevents metabolic acidosis and reduces inflammation during normothermic machine perfusion of the vascularized composite allograft: A preclinical study. Artif Organs. 2021;46(2):259-272doi: 10.1111/aor.14089.
Stone, J. P., Amin, K. R., Geraghty, A., Kerr, J., Shaw, M., Dabare, D., Wong, J. K., Brough, D., Entwistle, T. R., Montero-Fernandez, A., & Fildes, J. E. (2022). Renal hemofiltration prevents metabolic acidosis and reduces inflammation during normothermic machine perfusion of the vascularized composite allograft: A preclinical study. Artificial organs, 46(2), 259-272. https://doi.org/10.1111/aor.14089
Stone, John P, et al. "Renal hemofiltration prevents metabolic acidosis and reduces inflammation during normothermic machine perfusion of the vascularized composite allograft: A preclinical study." Artificial organs vol. 46,2 (2022): 259-272. doi: https://doi.org/10.1111/aor.14089
Stone JP, Amin KR, Geraghty A, Kerr J, Shaw M, Dabare D, Wong JK, Brough D, Entwistle TR, Montero-Fernandez A, Fildes JE. Renal hemofiltration prevents metabolic acidosis and reduces inflammation during normothermic machine perfusion of the vascularized composite allograft: A preclinical study. Artif Organs. 2022 Feb;46(2):259-272. doi: 10.1111/aor.14089. Epub 2021 Nov 26. PMID: 34662442.
Copy Download .nbib Format: NLM
An inorganic propellane with central B-B bond.

Chemical communications (Cambridge, England)

Pospiech S, Brough S, Bolte M, Lerner HW, Bettinger HF, Wagner M.
PMID: 22565212
Chem Commun (Camb). 2012 Jun 14;48(47):5886-8. doi: 10.1039/c2cc32256k. Epub 2012 May 08.

9,10-Dihydroanthracene-9,10-diyl-bridged B(2)(NMe(2))(2) readily adds [H(2)NMe(2)](+), HCl and F(3)CCOOH across its partial B=N double bond(s), thereby forming mono- or diadducts; treatment with 1-iso-propyl-2-mercaptoimidazole leads to a triply B-B-bridged propellane-like structure.

Cite
Pospiech S, Brough S, Bolte M, et al. An inorganic propellane with central B-B bond. Chem Commun (Camb). 2012;48(47):5886-8doi: 10.1039/c2cc32256k.
Pospiech, S., Brough, S., Bolte, M., Lerner, H. W., Bettinger, H. F., & Wagner, M. (2012). An inorganic propellane with central B-B bond. Chemical communications (Cambridge, England), 48(47), 5886-8. https://doi.org/10.1039/c2cc32256k
Pospiech, Steffen, et al. "An inorganic propellane with central B-B bond." Chemical communications (Cambridge, England) vol. 48,47 (2012): 5886-8. doi: https://doi.org/10.1039/c2cc32256k
Pospiech S, Brough S, Bolte M, Lerner HW, Bettinger HF, Wagner M. An inorganic propellane with central B-B bond. Chem Commun (Camb). 2012 Jun 14;48(47):5886-8. doi: 10.1039/c2cc32256k. Epub 2012 May 08. PMID: 22565212.
Copy Download .nbib Format: NLM
Gut dysbiosis is associated with acceleration of lupus nephritis.

Scientific reports

Valiente GR, Munir A, Hart ML, Blough P, Wada TT, Dalan EE, Willis WL, Wu LC, Freud AG, Jarjour WN.
PMID: 34996983
Sci Rep. 2022 Jan 07;12(1):152. doi: 10.1038/s41598-021-03886-5.

The gut microbiota (GM) exerts a strong influence over the host immune system and dysbiosis of this microbial community can affect the clinical phenotype in chronic inflammatory conditions. To explore the role of the GM in lupus nephritis, we...

Cite
Valiente GR, Munir A, Hart ML, et al. Gut dysbiosis is associated with acceleration of lupus nephritis. Sci Rep. 2022;12(1):152doi: 10.1038/s41598-021-03886-5.
Valiente, G. R., Munir, A., Hart, M. L., Blough, P., Wada, T. T., Dalan, E. E., Willis, W. L., Wu, L. C., Freud, A. G., & Jarjour, W. N. (2022). Gut dysbiosis is associated with acceleration of lupus nephritis. Scientific reports, 12(1), 152. https://doi.org/10.1038/s41598-021-03886-5
Valiente, Giancarlo R, et al. "Gut dysbiosis is associated with acceleration of lupus nephritis." Scientific reports vol. 12,1 (2022): 152. doi: https://doi.org/10.1038/s41598-021-03886-5
Valiente GR, Munir A, Hart ML, Blough P, Wada TT, Dalan EE, Willis WL, Wu LC, Freud AG, Jarjour WN. Gut dysbiosis is associated with acceleration of lupus nephritis. Sci Rep. 2022 Jan 07;12(1):152. doi: 10.1038/s41598-021-03886-5. PMID: 34996983; PMCID: PMC8742035.
Copy Download .nbib Format: NLM
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.

Future oncology (London, England)

Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K, Quach H, Callander N, Minnema MC, Trudel S, Jackson NA, Ahlers CM, Im E, Cheng S, Smith L, Hareth N, Ferron-Brady G, Brouch M, Montes de Oca R, Paul S, Holkova B, Gupta I, Kremer BE, Richardson P.
PMID: 33682447
Future Oncol. 2021 Jun;17(16):1987-2003. doi: 10.2217/fon-2020-1269. Epub 2021 Mar 08.

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic...

Cite
Nooka AK, Weisel K, van de Donk NW, et al. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncol. 2021;17(16):1987-2003doi: 10.2217/fon-2020-1269.
Nooka, A. K., Weisel, K., van de Donk, N. W., Routledge, D., Otero, P. R., Song, K., Quach, H., Callander, N., Minnema, M. C., Trudel, S., Jackson, N. A., Ahlers, C. M., Im, E., Cheng, S., Smith, L., Hareth, N., Ferron-Brady, G., Brouch, M., Montes de Oca, R., Paul, S., Holkova, B., Gupta, I., Kremer, B. E., & Richardson, P. (2021). Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future oncology (London, England), 17(16), 1987-2003. https://doi.org/10.2217/fon-2020-1269
Nooka, Ajay K, et al. "Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design." Future oncology (London, England) vol. 17,16 (2021): 1987-2003. doi: https://doi.org/10.2217/fon-2020-1269
Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K, Quach H, Callander N, Minnema MC, Trudel S, Jackson NA, Ahlers CM, Im E, Cheng S, Smith L, Hareth N, Ferron-Brady G, Brouch M, Montes de Oca R, Paul S, Holkova B, Gupta I, Kremer BE, Richardson P. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncol. 2021 Jun;17(16):1987-2003. doi: 10.2217/fon-2020-1269. Epub 2021 Mar 08. PMID: 33682447.
Copy Download .nbib Format: NLM
Improved diabetes-related distress and self-efficacy outcomes in a self-management digital programme for people with type 2 diabetes, myDESMOND.

Diabetic medicine : a journal of the British Diabetic Association

Hadjiconstantinou M, Barker MM, Brough C, Schreder S, Northern A, Stribling B, Khunti K, Davies MJ.
PMID: 33675068
Diabet Med. 2021 May;38(5):e14551. doi: 10.1111/dme.14551. Epub 2021 Mar 15.

No abstract available.

Cite
Hadjiconstantinou M, Barker MM, Brough C, et al. Improved diabetes-related distress and self-efficacy outcomes in a self-management digital programme for people with type 2 diabetes, myDESMOND. Diabet Med. 2021;38(5):e14551doi: 10.1111/dme.14551.
Hadjiconstantinou, M., Barker, M. M., Brough, C., Schreder, S., Northern, A., Stribling, B., Khunti, K., & Davies, M. J. (2021). Improved diabetes-related distress and self-efficacy outcomes in a self-management digital programme for people with type 2 diabetes, myDESMOND. Diabetic medicine : a journal of the British Diabetic Association, 38(5), e14551. https://doi.org/10.1111/dme.14551
Hadjiconstantinou, Michelle, et al. "Improved diabetes-related distress and self-efficacy outcomes in a self-management digital programme for people with type 2 diabetes, myDESMOND." Diabetic medicine : a journal of the British Diabetic Association vol. 38,5 (2021): e14551. doi: https://doi.org/10.1111/dme.14551
Hadjiconstantinou M, Barker MM, Brough C, Schreder S, Northern A, Stribling B, Khunti K, Davies MJ. Improved diabetes-related distress and self-efficacy outcomes in a self-management digital programme for people with type 2 diabetes, myDESMOND. Diabet Med. 2021 May;38(5):e14551. doi: 10.1111/dme.14551. Epub 2021 Mar 15. PMID: 33675068.
Copy Download .nbib Format: NLM
Showing 145 to 150 of 150 entries